Stay updated with breaking news from Generally Safe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Takeda TSE4502NYSETAK today announced positive topline results from a randomized doubleblind placebocontrolled multiple dose Phase 2b trial evaluating TAK861 an oral orexin receptor 2 OX2R agonist in patients with narcolepsy type 1.
− Primary and Key Secondary Endpoints Were Met in Narcolepsy Type 1 Phase 2b Trial− TAK-861 Was Found to be Generally Safe and Well-Tolerated− Results Will be Presented at an Upcoming Scientific CongressOSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced positive topline resu...
Preliminary Data Shows that Arbutus' Capsid Inhibitor, AB-836 is Generally Safe and Well-Tolerated and Provides Robust Antiviral Activity WARMINSTER, Pa., Dec. 01, 2021 --... | December 1, 2021